
Current Price | $0.65 | Mkt Cap | $1.8M |
---|---|---|---|
Open | $0.64 | P/E Ratio | -0.10 |
Prev. Close | $0.65 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.63 - $0.67 | Volume | 196,003 |
52-Wk Range | $0.63 - $12.64 | Avg. Daily Vol. | 444,944 |
Current Price | $0.65 | Mkt Cap | $1.8M |
---|---|---|---|
Open | $0.64 | P/E Ratio | -0.10 |
Prev. Close | $0.65 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.63 - $0.67 | Volume | 196,003 |
52-Wk Range | $0.63 - $12.64 | Avg. Daily Vol. | 444,944 |
The best Bull and Bear pitches based on recency and number of recommendations.
In retrospect, passing over NovaBay in November when it dropped to 0.9 in the wake of the failure of the impetigo trial was a clear missed opportunity. Even though I believe the company and its particular twitch on bleach dilution are hopeless for… More
Uses known stock pump and dump promoter Redchip.com. Garbage.
Read the most recent pitches from players about NBY.
Recs
Currently underpriced.
Recs
Uses known stock pump and dump promoter Redchip.com. Garbage.
Recs
I think NBY will have tremendous growth in the next 2 years. They've got one product on the market (Neutrophase), and it's picking up steam in the US and China. They've also got clinical trials that have yielded positive results, and should have more trial results soon. They've also got a little influx of cash from their partnership with China Pioneer Pharma Holdings Limited, which will help their solvency prospects in the near term. I'm as encouraged about the Neutrophase prospects as I am about their trials for a treatment to the adenovirus (BAYNovation).
Find the members with the highest scoring picks in NBY.
marcjones281 (< 20) Score: +318.60
The Score Leader is the player with the highest score across all their picks in NBY.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
marcjones281 | < 20 | 1/19/2012 |
![]() |
5Y | $42.25 | -98.46% | +220.14% | +318.60 | 0 Comment | |
allstar31 | 99.95 | 9/12/2014 |
![]() |
5Y | $22.50 | -97.11% | +109.99% | +207.09 | 1 Comment | |
jasonrivera | 27.30 | 1/13/2016 |
![]() |
5Y | $2.28 | -71.45% | +122.11% | +193.55 | 0 Comment | |
warrenout | 31.86 | 1/4/2016 |
![]() |
5Y | $1.95 | -66.62% | +109.58% | +176.19 | 0 Comment | |
drugtrader | 56.77 | 6/25/2020 |
![]() |
5Y | $1.07 | -39.16% | +37.83% | -76.99 | 0 Comment | |
BowtieBird | 46.42 | 11/16/2022 |
![]() |
1Y | $2.75 | -76.33% | +5.90% | -82.22 | 1 Comment | |
akakoolestkat | 45.88 | 3/22/2016 |
![]() |
3Y | $2.35 | -72.30% | +104.77% | -177.07 | 0 Comment | |
rajalonghorn | < 20 | 2/25/2014 |
![]() |
1Y | $32.50 | -98.00% | +127.09% | -225.08 | 0 Comment | |
peregrine | 90.02 | 4/7/2014 |
![]() |
5Y | $27.75 | -97.65% | +127.69% | -225.34 | 0 Comment | |
timc1981 | 58.32 | 2/12/2014 |
![]() |
5Y | $30.00 | -97.83% | +130.20% | -228.03 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.